Wemos in de Telegraaf: subsidies have made Zolgensma and its high price possible

8/8/2019 - News

1.9 million Euro. It is expected that that will be the price of the medicine Zolgensma, manufactured by the pharmaceutical company Novartis. At the end of this month, the European Medicines Agency (EMA) will give approval for this medicine. The Dutch newspaper De Telegraaf recently interviewed our global health advocate Ella Weggen about how the current medicines policy in the Netherlands has made the ludicrously high price of 1.9 million Euro possible.

Read more in the article in De Telegraaf (Dutch).

Photo: Venus Veldhoen

 

 

 

Back to the overview

Read more news

News
20/11/2024

Pandemic agreement negotiations reveal key divides and finance gap

Member states of the World Health Organization gathered in Geneva from 4 – 15 November for the 12th round of negotiations on a pandemic agreement. Progress is slow, stumbling blocks including access to medical countermeasures, sharing of knowledge and technology and investments in prevention and surveillance of disease outbreaks. Moreover, there is not enough attention for the need for equitable finance. Read more

Receive our newsletter

  • instagram
  • linkedin
  • youtube